Eisai will pay up to $2 billion in a deal with Bliss Biopharmaceutical to develop an antibody-drug conjugate, BB-1701, with the goal of treating solid tumors expressing HER2. The move is a sign of Eisai’s increased investment in ADCs. (Endpoints News)
Diabetes drugs used for weight loss like Ozempic and Wegovy are being examined for their potential to treat brain disorders like Alzheimer’s disease. Some diabetes drugs work on certain aspects of the metabolic system that are linked to Alzheimer’s disease and inflammation – and scientists say there’s growing evidence to suggest potential there. (Reuters)
Exelixis said Lance Willsey was leaving its board and that it would not contest the election of a dissident director candidate amid a proxy battle with investor Farallon Capital Management. “The board supports Dr. Willsey’s decision, which will end the need for Farallon to continue its proxy campaign,” Exelixis said in a statement. (Benzinga)
The federal government is funding a large study that is measuring whether safe injection sites – a harm reduction model – can help prevent drug overdoses. The government is providing funds to New York University and Brown University to study two NYC sites and one in Providence, R.I. (STAT News)
Elizabeth Holmes said Amanda Seyfried was “not playing me” in The Dropout. The disgraced Theranos CEO said it was a “character I created.” (The New York Times)
